IGF::OT::IGF, R&D - VASCULAR INTERVENTION/INNOVATIONS THERAPEUTIC ADVANCES

IGF::OT::IGF，R

• 批准号: 9201155
• 负责人: KAREN HANSEN
• 金额: $ 43.78万
• 依托单位: CCS ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-11-15 至 2016-11-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9201155
• 关键词: Advisory Committees; Blood Vessels; Development; Diagnostic; Disease; Instruction; Intervention; Medical; Modality; National Heart, Lung, and Blood Institute; Pulmonary Hypertension; Research; Research Personnel; Resources; Secure; Services; Site; Site Visit; Staging; Support Contracts; Teleconferences; Therapeutic; Training; Vascular Diseases; innovation; meetings; product development; programs; research and development

The Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program is a new translational initiative of the National Heart, Lung, and Blood Institute (NHLBI) that enables and accelerates the development of promising diagnostic and therapeutic modalities for unmet and underserved medical needs. The VITA Program provides contract support for early-stage translational development of product candidates in the fields of vascular disorders, thrombotic diseases, and pulmonary hypertension.

血管干预/创新和治疗进展（VITA）计划是国家心脏、肺和血液研究所（NHLBI）的一项新的转化倡议，旨在实现和加速有前途的诊断和治疗模式的发展，以满足未满足和服务不足的医疗需求。VITA项目为血管疾病、血栓性疾病和肺动脉高压领域候选产品的早期转化开发提供合同支持。